oral administration of auranofin on consecutive days from 6 weeks of age reduced anti-dna antibody production , igm rheumatoid factor production , hypergammaglobulinemia , polyclonal b cell activation and renal disease , but did not prevent massive lymphadenopathy or restore the low level of either il-2 production or mitogen response associated with 1pr gene .
C0004320
auranofin
C0022658
renal